These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24342636)

  • 1. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.
    Rao GG; Ly NS; Haas CE; Garonzik S; Forrest A; Bulitta JB; Kelchlin PA; Holden PN; Nation RL; Li J; Tsuji BT
    Antimicrob Agents Chemother; 2014; 58(3):1381-8. PubMed ID: 24342636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bergen PJ; Li J; Nation RL; Turnidge JD; Coulthard K; Milne RW
    J Antimicrob Chemother; 2008 Mar; 61(3):636-42. PubMed ID: 18227094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
    Bergen PJ; Bulitta JB; Kirkpatrick CM; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Lipman J; Roberts JA; Landersdorfer CB
    J Antimicrob Chemother; 2016 Sep; 71(9):2509-20. PubMed ID: 27231278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
    Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin Combinations Combat
    Bulman ZP; Chen L; Walsh TJ; Satlin MJ; Qian Y; Bulitta JB; Peloquin CA; Holden PN; Nation RL; Li J; Kreiswirth BN; Tsuji BT
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
    Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.
    Córdoba J; Coronado-Álvarez NM; Parra D; Parra-Ruiz J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7316-9. PubMed ID: 26369956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.